drugset / Trial / NCT03733561

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

NCT03733561

Phase 1 Completed 40 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers

Timeline

Start
2018-11-09
Primary completion
2018-12-23
Completion
2018-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject LY03003 Unknown Intramuscular
Comparator Rotigotine Unknown 4 mg Other

Indications